CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
Anastrozole (Teva Pharmaceuticals USA) +1 moredrug
Likely dose
Anastrozole (Teva Pharmaceuticals USA) 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01182181
NCT01182181Phase 1Completed
CompareCT.gov

A Single-Dose, Comparative Bioavailability Study of Two Formulations of Anastrozole 1 mg Tablets Under Fasting Conditions

Teva Pharmaceuticals USA·interventional·Posted Aug 16, 2010·Updated Nov 15, 2010

In Brief

A Phase 1 clinical trial evaluating Anastrozole (Teva Pharmaceuticals USA) and Anastrozole (Arimidex®) for Healthy. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate the comparative bioavailability between Anastrozole 1 mg Tablets (Teva Pharmaceuticals USA) and Arimidex® 1 mg Tablets (AstraZeneca Pharmaceuticals LP, USA), after a single-dose in healthy subjects under fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 16, 2010
Enrollment StartAug 1, 2005
Primary CompletionSep 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.9 years ago

Interventions

Anastrozole (Teva Pharmaceuticals USA)drug

1 mg Tablets

Anastrozole (Arimidex®)drug

1 mg Tablets